Study details
Enrolling now
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Philip Kern
NCT IDNCT05051436ClinicalTrials.gov data as of Apr 2026
Phase
Phase 4
Target enrollment
96
Study length
about 4.1 years
Ages
35–65
Locations
1 site in KY
About this study
This trial is testing whether mirabegron, tadalafil, or both improve glucose control in people with prediabetes. Participants will take either mirabegron, tadalafil, a combination of the two, or a placebo for 14 weeks and their blood sugar levels will be monitored.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Mirabegron 50 MG
- 2.Take Placebo
- 3.Take Tadalafil 10 MG
PhasePhase 4
DrugMirabegron 50 MG
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low8%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
mirabegron, tadalafil
Drug routes
oral (Oral Tablet)
Endpoints
Secondary: Hemoglobin A1C
Body systems
Endocrinology